Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD), a common cause of chronic liver disease (CLD), has a global prevalence of 25%.1 Its progressive form, nonalcoholic steatohepatitis (NASH), is a leading indication for liver transplantation (LT) in the United States.2 As a result, specialty societies, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver, have developed guidance on the epidemiology, diagnosis, and treatment of NAFLD and NASH.4 Therefore, the transplant team must be well versed in the state of current knowledge about NAFLD and transplant‐specific issues for this increasingly important indication for LT. Liver Transplantation 24 166–170 2018 AASLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 10×
“The most common cause of death in NAFLD and NASH patients, however, is cardiovascular disease (CVD) with liver-related mortality among the top 3.((4,6)) To quantify liver-related and overall mortality rates, a meta-analysis suggested these rates among NAFLD and NASH to be 0.”
BackgroundMethodSelf-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationCause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283 · cited 6×
“Given that this is a dynamic field, there is a rush to identify and validate a noninvasive test for NASH or NASH with fibrosis((4,6,7,17)) for FDA approval.”
BackgroundMethodInfluentialCusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Cited by
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
“Their models predict that more than 39 million people will have NAFLD, with annual direct medical costs of approximately $62 billion ($1,584 per patient) in the US.”
BackgroundInfluentialSelf-citationMilosevic, I., Vujovic, A., Barac, A., Djelic, M., Korac, M., Radovanovic Spurnic, A., Gmizic, I., Stevanovic, O., Djordjevic, V., Lekic, N., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020395 · Cited by 551
Epidemiology of chronic liver diseases in the USA in the past three decades
Younossi, Z. M., Stepanova, M., Younossi, Y., Golabi, P., Mishra, A., Rafiq, N., & Henry, L. (2020) · Gut · doi:10.1136/gutjnl-2019-318813 · Cited by 549
Self-citationYounossi, Z. M., Marchesini, G., Pinto-Cortez, H., & Petta, S. (2019) · Transplantation · doi:10.1097/tp.0000000000002484 · Cited by 404
Self-citationGolabi, P., Paik, J. M., AlQahtani, S., Younossi, Y., Tuncer, G., & Younossi, Z. M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.022 · Cited by 259
Self-citation
Metadata
- Authors
- Younossi, Z. M.
- Venue
- Liver Transplantation
- Published
- 2018-01-29
- Volume
- 24
- Issue
- 2
- Pages
- 166-170
- ISSN
- 1527-6465 (ISSN-L)
- 1527-6473
- OpenAlex
- W2777595263
- Cited by
- 73
- References
- 5
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. https://app.cochat.ai/papers/10.1002/lt.25003
- The paper
- Younossi, Z. M. (2018). Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. Liver Transplantation. https://doi.org/10.1002/lt.25003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.